Welcome to Seeking Alpha's Wall Street Lunch. Our afternoon update on today's market action news and analysis.

Good afternoon. Today is Tuesday, February 6th, and I'm your host, Kim Kahn. Our top story so far.

Sales of obesity drugs are soaring. Eli Lilly posted better than expected Q4 results,

as sales for its new diabetes and weight loss therapies handily topped

Wall Street estimates. The drugmaker reported 9.4 billion in revenue for the quarter,

up 28% year on year, as sales from its GLP1 agonists,

Monjaro and Wigovi, indicated for diabetes and weight loss,

surge despite competition from its EU rival Novo Nordisk.

Monjara and Wagovi generated 2.2 billion and 135.8 million in revenue respectively.

The Bloomberg consensus was for Wangearo sales of 1.8 billion and Wagovey sales of $140.7 million.

However, Lily's blockbuster diabetes drug trulicity underperformed.

Revenue of 1.7 billion was down 14% year over year.

Its plaques suriocese therapy taults was also disappointing.

Among other active stocks, BP rose after saying it will accelerate stock buybacks through the end of the next year,

despite reporting a sharp drop in Q4 profits.

BP beat expectations with a less than expected drop in its underlying replacement cost profit

to 2.99 billion from 4.81 billion in the year earlier quarter.

Most of the profit came from gains in oil production and operations, where profit before interest in taxes rose to 3.55 billion from 3.14 billion.

DuPont raised its dividend and approved more stock buybacks.

The announcement followed an earlier warning about slower sales amid weakness in China and after

takeover talks stalled docuSign said it will cut its head count by roughly 6% or

400 employees with the majority of cuts coming in sales and marketing.

...